Yasmin Safety Label Updates

Yasmin (drospirenone and ethinyl estradiol) is a prescription oral contraceptive used to prevent pregnancy. Yasmin was first introduced in 2001 and was the first birth control pill to contain the progestin drospirenone.

Blood Tests Recommended

Most of Yasmin problems are linked to the use of drospirenone, which works against the body's normal regulation of balance between salt and water. This can cause elevated potassium levels, which is known to cause serious heart problems. The product labeling and package insert for Yasmin recommends that blood tests be performed to check users' potassium levels within the first month of use. Such blood tests are not necessary for any other types of birth control pills.

Yasmin Is on Public Citizen's "Do Not Use" List

The Public Citizen Consumer advocacy group listed Yasmin as a "Do Not Use" drug in April 2002 due to side effects caused by drospirenone. Side effects noted include increases in blood levels of potassium, which can result in heart problems and other dangerous health concerns. In addition, there is not evidence that the drug is better than other contraceptives or that the benefits of Yasmin use outweighs the risks.

Bayer's Advertising Campaign

Bayer, the manufacturer of Yasmin has received several warning letters from the U.S. Food and Drug Administration (FDA), regarding the accuracy of their advertising campaigns for Yasmin.

Advocacy groups claim that Bayer has known about the risk of potential Yasmin problems for some time and that multiple studies have established the potential risk of life-threatening injures. Despite the known risks, the drug makers have continued to market Yasmin without adequate warnings and introduced "Yaz", another oral contraceptive containing drospirenone, which also carries the same risks.

Consult a Lawyer

If you or a loved one has been harmed by Yasmin, you should contact a Yasmin attorney to find out whether you are eligible for compensation for your injuries.

Share |

Keyword Tags: defective drugs, pharmaceutical litigation

Still Have a Question? Ask a Lawyer in Your Area